Biotech
Seeking innovative breakthroughs with the power to change therapeutic paradigmsDementia
Investing in innovative therapeutics for dementiaHealthcare Growth
Growth capital and liquidity for industry leaders transforming healthcareMedtech
Compelling teams and technologies with the power to change medicine
Our goal is to transform healthcare one investment at a time.
By supporting diverse entrepreneurs who create and build breakthrough companies and treatments.
Discover our PortfolioWe empower innovators to improve patients’ lives.
And we have the track record to prove it.
- $3.7Bin historical commitments
Global private equity and venture capital investment platform. Specialized and diversified healthcare funds spanning all sectors and stages. Three teams focused on biotechnology (inc dementia), healthcare growth equity and medtech.
View our Strategies - 75IPOs/M&As
Backing inspiring and talented innovators with diverse experiences to create healthcare industry leaders that attract strategic acquirers and public investors. Our portfolio companies’ remarkable work benefits patients while growing shareholder value for investors.
View our Portfolio - 30yrtrack record in US and UK
One of the longest-tenured healthcare investment managers in the world. Experienced team of >50 investment professionals and operating partners based in Boston and London, adding value and guiding strategic direction.
Meet our People
Our People
SV is driven by our talented team and network. We bring together our experienced investment professionals with healthcare industry veterans to build value in breakthrough life sciences companies.
Meet our PeopleThe latest from SV
We're proud to share our achievements and those of our portfolio companies.
- Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
- AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
- Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024